Singapore markets close in 17 minutes

AZN Jan 2025 95.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.2000-0.1000 (-7.69%)
As of 02:41PM EDT. Market open.
Full screen
Previous close1.3000
Open1.2000
Bid1.0100
Ask1.1500
Strike95.00
Expiry date2025-01-17
Day's range1.2000 - 1.2000
Contract rangeN/A
Volume5
Open interest2.57k
  • Simply Wall St.

    Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration

    The United Kingdom's financial markets are currently poised at a critical juncture, with the FTSE 100's movements closely tied to the upcoming release of May's inflation data and decisions from the Bank of England. Amid these market conditions, identifying undervalued stocks can offer investors potential opportunities for growth in a fluctuating economic environment.

  • Zacks

    AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

    AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.

  • Benzinga

    Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment

    AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca